Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Vitiligo

Vitiligo

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Vitiligo

18 trials tracked for Vitiligo: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 5 citations.

18Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 9 Other / NA 8
  1. Phase 3 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Completed · 5 cited
  2. Phase 2 Topical Ruxolitinib for the Treatment of Vitiligo Completed
  3. Phase 2 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo Completed
  4. Phase 2 A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo Completed
  5. Phase 2 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Completed
  6. Phase 2 Evaluation of AMG 714 for Vitiligo Completed
Show 12 more trials
  1. Phase 2 Tofacitinib for Immune Skin Conditions in Down Syndrome Completed
  2. Phase 2 A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) Completed
  3. Phase 2 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV) Completed
  4. Phase 2 Clinical Trial of Simvastatin to Treat Generalized Vitiligo Completed
  5. N/A Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo Completed
  6. N/A Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy Completed
  7. N/A Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions Completed
  8. N/A PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation Completed
  9. N/A Mental Health Associations With Vitiligo Completed
  10. N/A Investigating Healthcare Disparities in Vitiligo Completed
  11. N/A The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands Completed
  12. N/A Photocil (Topical) for the Treatment of Vitiligo Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Vitiligo: what the trials found

Ruxolitinib has demonstrated significant efficacy in improving facial vitiligo scores. In a Phase 3 trial, patients receiving ruxolitinib showed high rates of improvement, with approximately 98.2% achieving a ≥50% improvement in F-VASI scores and 96.4% achieving a ≥75% improvement during the extension period 1.

Ruxolitinib cream was shown to significantly improve facial vitiligo compared to vehicle at week 24, where 45.5% of patients achieved a ≥50% improvement in F-VASI scores (p=0.0057) 6. However, significant improvements in full-body assessment (T-VASI) were not statistically confirmed at week 52 6.

Ruxolitinib cream treatment was associated with a reduction in the immune biomarker CXCL10 at week 4 and week 24, with these changes correlating significantly to efficacy readouts (p=0.004) 5.

Recent results — preliminary, needs further review

  • Tofacitinib showed significant improvements in whole blood transcriptome interferon (IFN) scores (p=0.00000621), Investigator's Global Assessment (IGA) (p=0.00000061), and Dermatology Life Quality Index (DLQI) (p=0.00000004) 2.
  • AMG 714 did not show statistically significant improvements in F-VASI35 or F-VASI25 scores at various time points through week 48 3.

For the clinician treating this condition

  • Ruxolitinib is established as an effective treatment for facial vitiligo, with high percentages of patients achieving significant improvements in F-VASI scores [1, 6].
  • Ruxolitinib cream demonstrates a correlation between the reduction of inflammatory biomarkers (CXCL10) and clinical efficacy 5.
  • Tofacitinib shows promise in improving both biological markers (IFN score) and patient-reported quality of life (DLQI) 2.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata
Cardiology Sys. Review
Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata One drug improved skin, hair, and pigment in one man
A 57-year-old man with severe, refractory skin conditions showed significant improvement in dermatitis, vitiligo, and hair loss on upadaciti…
A single patient with three skin conditions saw dramatic improvement after taking upadacitinib for one year.
Frontiers Jun 9, 2026
Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts
Rheumatology Sys. Review
Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts New light therapies and skin grafts offer hope for vitiligo patients
This narrative review synthesizes current evidence on phototherapy for vitiligo, highlighting narrowband UVB as the mainstay. Excimer lasers…
A review of treatments for vitiligo highlights options like narrowband ultraviolet B light, excimer therapy, and cellular grafting that may …
Frontiers Jun 6, 2026
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients
Allergy & Immunology Sys. Review
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients Review shows immune cells may be off in vitiligo
This narrative review examines Treg biology and immunoregulatory functions alongside NB-UVB, JAK inhibitors, and low-dose IL-2 in vitiligo p…
A review finds immune cells that calm inflammation are fewer and less effective in people with vitiligo, suggesting a path for future treatm…
Frontiers May 18, 2026
Hair follicle-derived epithelial sheet transplantation shows repigmentation in stable vitiligo patients
Dermatology
Hair follicle-derived epithelial sheet transplantation shows repigmentation in stable vitiligo patients Could hair follicles help restore skin color in vitiligo?
In patients with stable vitiligo, transplantation of hair follicle-derived epithelial sheets resulted in skin repigmentation.
Doctors transplanted cells from hair follicles onto vitiligo skin, restoring natural color in patients with stable disease.
medRxiv Apr 3, 2026

Questions about Vitiligo

Is there evidence that upadacitinib helps treat concurrent Vitiligo and alopecia areata?

Yes, a case report shows upadacitinib 15 mg daily improved vitiligo repigmentation and alopecia areata hair regrowth in a patient with both conditions.

Full answer →
Are JAK inhibitors used as an addition to phototherapy for Vitiligo?

Yes, JAK inhibitors are increasingly used as an addition to phototherapy for vitiligo, with studies showing enhanced repigmentation when combined with narrowband UVB.

Full answer →